1. Capsule composition soderzhaschiyinkapsulirovanny material containing {[(1R, 2R) -2- [4- (4-cyanophenyl) -1,3-thiazol-2-yl] -1- (2,4-difluorophenyl) -1 - (1H-1,2,4-triazol-1-ylmethyl) propyl] oxy} metildigidrofosfat, or a pharmacologically acceptable salt or solvate of any of the foregoing iobolochku capsules not containing zhelatin.2. Capsule composition according to Claim. 1, characterized in that the capsule shell is formed the basis capsule shell containing starch, pullulan, polyvinyl alcohol or gipromellozu.3. Capsule composition according to Claim. 1, characterized in that the capsule shell is formed the basis capsule shell comprising pullulan or gipromellozu.4. Capsule composition according to Claim. 1, characterized in that the capsule shell is formed the basis capsule shell comprising gipromellozu.5. Capsule composition according to any one of claims. 1-4, characterized in that {[(1R, 2R) -2- [4- (4-cyanophenyl) -1,3-thiazol-2-yl] -1- (2,4-difluorophenyl) -1- (1H-1,2,4-triazol-1-ylmethyl) propyl] oxy} metildigidrofosfat, or a pharmacologically acceptable salt or solvate of any of the foregoing is a L-lysine - {[{1R, 2R) -2- [4 - (4-cyanophenyl) -1,3-thiazol-2-yl] -1- (2,4-difluorophenyl) -1- (1H-1,2,4-triazol-1-ylmethyl) propyl] oxy} metildigidrofosfat ethanol (1/1/1) .6. Capsule composition according to any one of claims. 1-4, wherein said encapsulated material further comprises an oxide magniya.7. Capsule composition of claim. 5, characterized in that the encapsulated material further comprises magnesium oxide.1. Капсульный состав, содержащийинкапсулированный материал, содержащий {[(1R,2R)-2-[4-(4-цианофенил)-1,3-тиазол-2-ил]-1-(2,4-дифторфенил)-1-(1H-1,2,4-триазол-1-илметил)пропил]окси}метилдигидрофосфат, или его фармакологически приемлемую соль, или сольват любого из вышеупомянутого иоболочку капсулы, не содержащую желатин.2. Капсульный состав по п. 1, отличающийся тем, что оболочка капсулы образована основой оболочки капсулы, содержащей крахмал, пул
